Clinical trials: Advanced Malignant Tumor
Solid Tumor, Adult
Advanced or Recurrent Solid Tumors Treated With SHetA2
The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.
- Trial name
- Okgyn1 (NCT04928508)
- Testing
- OK-1
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer.
- Trial name
- NCT04752215
- Testing
- BI 765049, ezabenlimab
- Where
- 14 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal…
- Trial name
- NCT06480240
- Testing
- OBI-992
- Where
- 8 sites in United States, Taiwan
- Volunteers
- 117 people
- Sponsor
- OBI Pharma, Inc
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Advanced Malignant Solid Tumours
A Study of RT023 in Patients With Advanced Solid Tumors
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of RT023 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT07797426
- Testing
- RT023
- Volunteers
- 318 people
- Sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
This phase I/II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity
- Trial name
- NCT04021043
- Testing
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original…
- Trial name
- NCT07213817
- Testing
- IPN60300
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Ipsen
Advanced Malignant Solid Tumor
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
- Trial name
- NCT06592417
- Testing
- JSKN016 injection
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors
- Trial name
- NCT05036291
- Testing
- NB004 tablets
- Where
- 4 sites in United States, China
- Volunteers
- 25 people
- Sponsor
- Ningbo Newbay Technology Development Co., Ltd
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among patients with prostate, cervical, and rectal…
- Conditions
- Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05722288
- Testing
- Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Solid Tumor
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with…
- Trial name
- NCT00215501
- Testing
- Capecitabine, 5-Fluorouracil (5-FU), Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03831295
- Testing
- Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ronald Levy
Tumor, Solid
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .
- Trial name
- NCT06987500
- Testing
- XNW29016
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Evopoint Biosciences Inc.
Malignant Solid Tumour
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, dose-escalation trial in patients with advanced solid tumors. The trial comprises 2 stages: a dose escalation stage at 8 dose levels of 2, 5, 10, 20, 40, 60, 80, and 100 mg/day,and possibly…
- Trial name
- NCT01184807
- Testing
- OPB-51602
- Where
- 2 sites in Singapore
- Volunteers
- 51 people
- Sponsor
- Otsuka Beijing Research Institute
Advanced Solid Tumor
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
The Phase Ia study was designed to evaluate the tolerability, safety, PK, PD, immunogenicity and primary resistance of single therapy tumor activity in subjects with advanced or metastatic solid tumors who have failed standard…
- Trial name
- NCT04912466
- Testing
- Biological: IBI322
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.